New Technologies and Applications in Sacral Neuromodulation: An Update

S. De Wachter; C.H. Knowles; D.S. Elterman; M.J. Kennelly; P.A. Lehur; K.E. Matzel; S. Engelberg; P.E.V. Van Kerrebroeck

doi:10.1007/s12325-019-01205-z

New Technologies and Applications in Sacral Neuromodulation: An Update

S. De Wachter^*, C.H. Knowles, D.S. Elterman, M.J. Kennelly, P.A. Lehur, K.E. Matzel, S. Engelberg, P.E.V. Van Kerrebroeck

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Recently rechargeable devices have been introduced for sacral neuromodulation (SNM) with conditional safety for full-body magnetic resonance imaging (MRI). Currently a recharge-free SNM device represents the standard implant; however, it is only approved for MRI head scans. As further new technologies with broader MRI capabilities are emerging, the advantages as well as disadvantages of both rechargeable versus recharge-free devices will be briefly discussed in this commentary from the perspective of patients, healthcare professionals, and providers.

Original language	English
Pages (from-to)	637-643
Number of pages	7
Journal	Advances in Therapy
Volume	37
Issue number	2
DOIs	https://doi.org/10.1007/s12325-019-01205-z
Publication status	Published - 1 Feb 2020

Keywords

fecal incontinence
follow-up
magnetic resonance imaging
modulation
multicenter
overactive bladder
rechargeable battery
sacral neuromodulation
stimulation
stimulator
system
urology
SYSTEM
FOLLOW-UP
Urology
Overactive bladder
MODULATION
Fecal incontinence
FECAL INCONTINENCE
MULTICENTER
STIMULATION
Sacral neuromodulation
Stimulator
Rechargeable battery
Magnetic resonance imaging

Access to Document

10.1007/s12325-019-01205-zLicence: CC BY-NC

Cite this

@article{21355fb5218644768951a99b553e8a79,

title = "New Technologies and Applications in Sacral Neuromodulation: An Update",

abstract = "Recently rechargeable devices have been introduced for sacral neuromodulation (SNM) with conditional safety for full-body magnetic resonance imaging (MRI). Currently a recharge-free SNM device represents the standard implant; however, it is only approved for MRI head scans. As further new technologies with broader MRI capabilities are emerging, the advantages as well as disadvantages of both rechargeable versus recharge-free devices will be briefly discussed in this commentary from the perspective of patients, healthcare professionals, and providers.",

keywords = "fecal incontinence, follow-up, magnetic resonance imaging, modulation, multicenter, overactive bladder, rechargeable battery, sacral neuromodulation, stimulation, stimulator, system, urology, SYSTEM, FOLLOW-UP, Urology, Overactive bladder, MODULATION, Fecal incontinence, FECAL INCONTINENCE, MULTICENTER, STIMULATION, Sacral neuromodulation, Stimulator, Rechargeable battery, Magnetic resonance imaging",

author = "{De Wachter}, S. and C.H. Knowles and D.S. Elterman and M.J. Kennelly and P.A. Lehur and K.E. Matzel and S. Engelberg and {Van Kerrebroeck}, P.E.V.",

note = "Funding Information: This article, the Rapid Service and Open Access Fees were funded by Medtronic International Trading Sarl, Switzerland. Funding Information: Stefan De Wachter receives paid consulting fees from Medtronic as honoraria for invited speaker. Paul Lehur has consulting agreements with Medtronic and B.Braun. Charles Knowles and Klaus Matzel have management/advisory affiliations with a global advisory panel regarding SNM for pelvic indications (directly relating to this manuscript) and also have paid consulting agreements with Medtronic (lectures). Charles Knowles also receives research support from Medtronic and Saluda Medical. Dean Elterman received consultancy or speaker fees from Axonics, Astellas, Boston Scientific, Duchesnay, Medtronic, Pfizer and Procept BioRobotics. He received research grants from Bioness, Boston Scientific, Medtronic, and Procept Biorobotics. Michael Kennelly received research grants from Allergan, Amphora, Axonics, Cook Myosite, Dignify Therapeutics, Ipsen, Taris, Uro1, FemPulse and EBT Medical. He is a member of advisory boards of Boston Scientific, Coloplast, Laborie, Urovant and has received speaker honoraria from Astellas and Allergan. Stefan Engelberg is a Medtronic employee. Philip E.V. Van Kerrebroeck received consultancy or speaker fees from Astellas, AstraZeneca, Axonics, BlueWind, Ferring, Medtronic and Neuspera. Funding Information: This article, the Rapid Service and Open Access Fees were funded by Medtronic International Trading Sarl, Switzerland. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors contributed to the concept and design of the commentary and provided major editorial input on the earlier and final versions of the manuscript. Stefan De Wachter receives paid consulting fees from Medtronic as honoraria for invited speaker. Paul Lehur has consulting agreements with Medtronic and B.Braun. Charles Knowles and Klaus Matzel have management/advisory affiliations with a global advisory panel regarding SNM for pelvic indications (directly relating to this manuscript) and also have paid consulting agreements with Medtronic (lectures). Charles Knowles also receives research support from Medtronic and Saluda Medical. Dean Elterman received consultancy or speaker fees from Axonics, Astellas, Boston Scientific, Duchesnay, Medtronic, Pfizer and Procept BioRobotics. He received research grants from Bioness, Boston Scientific, Medtronic, and Procept Biorobotics. Michael Kennelly received research grants from Allergan, Amphora, Axonics, Cook Myosite, Dignify Therapeutics, Ipsen, Taris, Uro1, FemPulse and EBT Medical. He is a member of advisory boards of Boston Scientific, Coloplast, Laborie, Urovant and has received speaker honoraria from Astellas and Allergan. Stefan Engelberg is a Medtronic employee. Philip E.V. Van Kerrebroeck received consultancy or speaker fees from Astellas, AstraZeneca, Axonics, BlueWind, Ferring, Medtronic and Neuspera. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Please note, contrary to the journal?s standard single-blind peer review process, as a commentary this article underwent review by a member of the journal?s Editorial Board. Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2020",

month = feb,

day = "1",

doi = "10.1007/s12325-019-01205-z",

language = "English",

volume = "37",

pages = "637--643",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - New Technologies and Applications in Sacral Neuromodulation: An Update

AU - De Wachter, S.

AU - Knowles, C.H.

AU - Elterman, D.S.

AU - Kennelly, M.J.

AU - Lehur, P.A.

AU - Matzel, K.E.

AU - Engelberg, S.

AU - Van Kerrebroeck, P.E.V.

N1 - Funding Information: This article, the Rapid Service and Open Access Fees were funded by Medtronic International Trading Sarl, Switzerland. Funding Information: Stefan De Wachter receives paid consulting fees from Medtronic as honoraria for invited speaker. Paul Lehur has consulting agreements with Medtronic and B.Braun. Charles Knowles and Klaus Matzel have management/advisory affiliations with a global advisory panel regarding SNM for pelvic indications (directly relating to this manuscript) and also have paid consulting agreements with Medtronic (lectures). Charles Knowles also receives research support from Medtronic and Saluda Medical. Dean Elterman received consultancy or speaker fees from Axonics, Astellas, Boston Scientific, Duchesnay, Medtronic, Pfizer and Procept BioRobotics. He received research grants from Bioness, Boston Scientific, Medtronic, and Procept Biorobotics. Michael Kennelly received research grants from Allergan, Amphora, Axonics, Cook Myosite, Dignify Therapeutics, Ipsen, Taris, Uro1, FemPulse and EBT Medical. He is a member of advisory boards of Boston Scientific, Coloplast, Laborie, Urovant and has received speaker honoraria from Astellas and Allergan. Stefan Engelberg is a Medtronic employee. Philip E.V. Van Kerrebroeck received consultancy or speaker fees from Astellas, AstraZeneca, Axonics, BlueWind, Ferring, Medtronic and Neuspera. Funding Information: This article, the Rapid Service and Open Access Fees were funded by Medtronic International Trading Sarl, Switzerland. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors contributed to the concept and design of the commentary and provided major editorial input on the earlier and final versions of the manuscript. Stefan De Wachter receives paid consulting fees from Medtronic as honoraria for invited speaker. Paul Lehur has consulting agreements with Medtronic and B.Braun. Charles Knowles and Klaus Matzel have management/advisory affiliations with a global advisory panel regarding SNM for pelvic indications (directly relating to this manuscript) and also have paid consulting agreements with Medtronic (lectures). Charles Knowles also receives research support from Medtronic and Saluda Medical. Dean Elterman received consultancy or speaker fees from Axonics, Astellas, Boston Scientific, Duchesnay, Medtronic, Pfizer and Procept BioRobotics. He received research grants from Bioness, Boston Scientific, Medtronic, and Procept Biorobotics. Michael Kennelly received research grants from Allergan, Amphora, Axonics, Cook Myosite, Dignify Therapeutics, Ipsen, Taris, Uro1, FemPulse and EBT Medical. He is a member of advisory boards of Boston Scientific, Coloplast, Laborie, Urovant and has received speaker honoraria from Astellas and Allergan. Stefan Engelberg is a Medtronic employee. Philip E.V. Van Kerrebroeck received consultancy or speaker fees from Astellas, AstraZeneca, Axonics, BlueWind, Ferring, Medtronic and Neuspera. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Please note, contrary to the journal?s standard single-blind peer review process, as a commentary this article underwent review by a member of the journal?s Editorial Board. Publisher Copyright: © 2019, The Author(s).

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Recently rechargeable devices have been introduced for sacral neuromodulation (SNM) with conditional safety for full-body magnetic resonance imaging (MRI). Currently a recharge-free SNM device represents the standard implant; however, it is only approved for MRI head scans. As further new technologies with broader MRI capabilities are emerging, the advantages as well as disadvantages of both rechargeable versus recharge-free devices will be briefly discussed in this commentary from the perspective of patients, healthcare professionals, and providers.

AB - Recently rechargeable devices have been introduced for sacral neuromodulation (SNM) with conditional safety for full-body magnetic resonance imaging (MRI). Currently a recharge-free SNM device represents the standard implant; however, it is only approved for MRI head scans. As further new technologies with broader MRI capabilities are emerging, the advantages as well as disadvantages of both rechargeable versus recharge-free devices will be briefly discussed in this commentary from the perspective of patients, healthcare professionals, and providers.

KW - fecal incontinence

KW - follow-up

KW - magnetic resonance imaging

KW - modulation

KW - multicenter

KW - overactive bladder

KW - rechargeable battery

KW - sacral neuromodulation

KW - stimulation

KW - stimulator

KW - system

KW - urology

KW - SYSTEM

KW - FOLLOW-UP

KW - Urology

KW - Overactive bladder

KW - MODULATION

KW - Fecal incontinence

KW - FECAL INCONTINENCE

KW - MULTICENTER

KW - STIMULATION

KW - Sacral neuromodulation

KW - Stimulator

KW - Rechargeable battery

KW - Magnetic resonance imaging

U2 - 10.1007/s12325-019-01205-z

DO - 10.1007/s12325-019-01205-z

M3 - Editorial

C2 - 31875299

SN - 0741-238X

VL - 37

SP - 637

EP - 643

JO - Advances in Therapy

JF - Advances in Therapy

IS - 2

ER -